Seres Q1 2026 net loss $19.9M; cash runway only through Q3 2026

Seres Therapeutics, Inc.

2026-Q1 EPS reported -$2.08 revenue$358,000

Net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé payment).
Cash and equivalents $29.8M as of March 31, 2026; expects to fund ops only through Q3 2026.
R&D expenses $13.2M (up from $11.8M), G&A $8.1M (down from $11.9M); no manufacturing services expenses.
SER-155 IST for immune checkpoint inhibitor-related enterocolitis enrollment complete (15 pts); data expected in coming weeks.
SER-155 Phase 2 ready for allo-HSCT but seeking funding; SER-603 preclinical for IBD with IND-enabling activities ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Seres Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $19.9 million for the first quarter of 2026.

Period: the quarter ended March 31, 2026
Net income: Net loss was $19.9 million for the first quarter of 2026
Result: reported results

Exact text from the filing

Seres Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and provided operational updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-205009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.